Medical weight management is a personalized, medically guided approach designed to support patients who are struggling to lose weight, maintain weight loss, or improve health factors connected to excess weight. It goes beyond willpower, crash diets, or short-term programs and instead treats weight as a complex metabolic issue influenced by appetite signaling, insulin response, satiety, lifestyle, and overall health. At Juniper, this means building a plan around the individual patient rather than forcing a generic formula. For many patients, that plan may include semaglutide or tirzepatide, two once-weekly injectable medications that work by improving fullness, reducing appetite, and supporting long-term weight management when paired with nutrition, movement, and clinical oversight (NIDDK; FDA Wegovy label; FDA Zepbound label). Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 pathways, which is part of why both have become such important tools in modern obesity medicine (FDA Wegovy label; FDA Zepbound label).